Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.22, in-line with the analyst estimate of $0.22. Revenue for the quarter came in at $48.2 million versus the consensus estimate of $48.6 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.